Navigation Links
Lixte Biotechnology Receives US Patent for Its Proprietary Histone Deacetylase Inhibitor
Date:4/4/2012

EAST SETAUKET, N.Y., April 4, 2012 /PRNewswire/ -- Lixte Biotechnology Holdings, Inc. announced receiving an official notice of allowance from the United States Patent and Trademark Office for its lead histone deacetylase inhibitor (HDACi), LB-201 and other structural homologs.

Dr. John Kovach, founder and president of Lixte, said, "Although there are HDACi approved for certain types of skin lymphomas and many other HDACi in various stages of development, our compounds have characteristics which may be advantageous for clinical use.  The Lixte compounds also have broad anti-cancer activity but in addition have 1) potential for the treatment of neurodegenerative diseases, for which Lixte recently announced a USPTO patent approval, 2) activity (LB-205) against the lysosomal storage disease, Gaucher Disease, as recently reported in the Proceedings of the National Academy of Science, USA (Dec. 27 2011; 108:21200-5) and 3) curative anti-fungal activity applied topically (LB-201) against the most common skin fungal infections of humans and domestic animals in guinea pig models. As Lixte is predominantly focused on cancer treatment, it is seeking to license the non-neoplastic activities of its proprietary HDACi."

Dr. Kovach continued, "Lixte's primary goal at present is bringing its lead anti-cancer compound, LB-100, into Phase I trial.  We believe this inhibitor of serine/threonine phosphatase has the potential to be first-in-class and to have wide applicability for the treatment of diverse cancers.  LB-100 has completed pre-clinical toxicology and formulation with an anticipated IND submission for FDA approval of a Phase I trial this spring."

About Lixte Biotechnology Holdings, Inc.

Lixte is a cancer drug discovery company, combining selection of novel targets from the medicinal chemistry and molecular biology literature with innovative synthetic chemistry to develop new potentially more effective anti-cancer drugs. It has l
'/>"/>

SOURCE Lixte Biotechnology Holdings, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Lixte Biotechnology Holdings Announces New Appointment to Board of Directors
2. Lixte Biotechnology Holdings Lead Compound, LB-1.2, Enhances the Effectiveness of Standard Cancer Chemotherapy in Animal Models
3. Lixte Biotechnology Holdings Announces New Appointment to Board of Directors
4. Lixte Biotechnology Holdings Announces Filing of a New Patent Application for Cancer Therapy Based on Targeting a Biomarker by Novel Investigational Agents
5. Apexigen and Shanghai Duyiwei Biotechnology Co. Ltd Sign a License and Collaboration Agreement to Develop and Commercialize APX004
6. Global Biotechnology Industry
7. JumpStart Invests $250,000 in Milo Biotechnology
8. Puma Biotechnology Announces Positive PB272 (Neratinib) Phase II Data at CTRC-AACR San Antonio Breast Cancer Symposium
9. The European Union Signs Grant Contract to Fund a 2 Million Euro Biotechnology Research Project Led by Hadassah College Jerusalem
10. Animal Biotechnology - Technologies, Markets and Companies
11. Puma Biotechnology Announces Completion of Private Placement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... , September 18, 2014 /PRNewswire/ ... Markets ( http://www.researchandmarkets.com/research/czvg3s/biocompatible ) has announced ... Materials - Global Strategic Business Report" ... (Logo: http://photos.prnewswire.com/prnh/20130307/600769) ,This report analyzes the ... US$ Million by the following Product ...
(Date:9/18/2014)... -- Research and Markets has announced the ... Industry Report, 2014-2017" report to their offering. ... can differentiate into specialized cells and can divide (through ... can be applied to treatment of cardiovascular diseases, leukemia ... damage or lesion of liver, kidney and other parenchymal ...
(Date:9/18/2014)... , Sept. 18, 2014 Research ... "Global Companion Diagnostics (Polymerase Chain Reaction, In-situ hybridization, ... report to their offering. The global ... CAGR of 22.7% from 2014 to 2019. Factors such ... growing adoption of companion diagnostics by the pharmaceutical industry, ...
(Date:9/18/2014)... , Sept. 18, 2014  MEI Pharma, Inc. (Nasdaq: ... clinical development of novel therapies for cancer, announced today that ... Officer, will present at BioCentury,s NewsMakers in the Biotech ... a.m. Eastern time from the Millennium Broadway Hotel & Conference ... webcast of the presentation can be accessed at www.meipharma.com ...
Breaking Biology Technology:Biocompatible Materials - Global Strategic Business Report 2014 2Biocompatible Materials - Global Strategic Business Report 2014 3Global and Chinese Stem Cell Industry Report, 2014-2017 2Global and Chinese Stem Cell Industry Report, 2014-2017 3Global Companion Diagnostics (Polymerase Chain Reaction, In-situ hybridization, Immunohistochemistry) Market - Trends & Forecasts to 2019 2Global Companion Diagnostics (Polymerase Chain Reaction, In-situ hybridization, Immunohistochemistry) Market - Trends & Forecasts to 2019 3MEI Pharma To Present At BioCentury's NewsMakers Conference 2MEI Pharma To Present At BioCentury's NewsMakers Conference 3
... Dialysis Catheter With Patented Triple Arterial Lumen ... ... /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals,Inc. (NASDAQ: ANPI , TSX: ANP) today ... catheter at the 2008,Society of Interventional Radiology (SIR) Annual Scientific Meeting ...
... 1:30 p.m. (Pacific Time); ... http://www.adventrx.com , SAN DIEGO, March 13 ... focused on in-licensing,developing and commercializing proprietary product candidates primarily ... financial,results for the fourth quarter and year ended December ...
... Brussels: THR), a biotechnology company focused on vascular,diseases, ... results for,the twelve month period ending 31 December ... to invest in its development,pipeline and has continued ... Highlights, - Successful placing of a total ...
Cached Biology Technology:Angiotech showcases its Hemostream(TM) Dialysis Catheter at the Society of Interventional Radiology (SIR) Annual Meeting 2Angiotech showcases its Hemostream(TM) Dialysis Catheter at the Society of Interventional Radiology (SIR) Annual Meeting 3Angiotech showcases its Hemostream(TM) Dialysis Catheter at the Society of Interventional Radiology (SIR) Annual Meeting 4Angiotech showcases its Hemostream(TM) Dialysis Catheter at the Society of Interventional Radiology (SIR) Annual Meeting 5ADVENTRX Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2007 Financial Results 2ADVENTRX Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2007 Financial Results 3ADVENTRX Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2007 Financial Results 4ADVENTRX Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2007 Financial Results 5ADVENTRX Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2007 Financial Results 6ADVENTRX Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2007 Financial Results 7ThromboGenics Announces 2007 Full Year Results 2ThromboGenics Announces 2007 Full Year Results 3ThromboGenics Announces 2007 Full Year Results 4
(Date:9/19/2014)... by researchers from several Harvard University labs in ... and aspiring researchers with the intellectual raw materials ... from soft, flexible materials. , With the advent ... advances in manufacturing technology, soft robotics is emerging ... from conventional rigid robot design, but working with ...
(Date:9/19/2014)... sense of fairness did not evolve for the sake ... the benefits of continued cooperation, so say Frans de ... review article about inequity aversion (IA), which is defined ... is published in Science . , Their ... IA-related studies to address their hypothesis that it is ...
(Date:9/19/2014)... shows that legume plants regulate their symbiotic relationship ... are transmitted through the plant structure from leaves ... bacteria-holding nodules in the roots. This collaborative study ... for Basic Biology, the Graduate University for Advanced ... Resource Science in Japan. , Legumes, an ...
Breaking Biology News(10 mins):Soft robotics 'toolkit' features everything a robot-maker needs 2Evolution of responses to (un)fairness 2Evolution of responses to (un)fairness 3For legume plants, a new route from shoot to root 2
... puzzled scientists, and several scenarios have been proposed to ... appeared virtually simultaneously on Asia, Europe and North America ... research using the latest evidence suggests a completely different ... sudden, rapid global warming drove the dispersal. , ...
... 18 HIV-positive subjects shows that HIV in the brain and ... in the blood and peripheral tissues. , Moreover, serious cognitive ... of a particular mutation in the HIV envelope gene. ... Brain. It was led by Satish K. Pillai, PhD, a ...
... eat together, and most people find it impossible to ... share just about everything, including their genes. But sometimes ... predicts both of them should. , Scientists at the ... understand how two people who are so similar biologically ...
Cached Biology News:Ancient global warming drove early primates' dispersal 2Viral genetic differences are possible key to HIV dementia 2Viral genetic differences are possible key to HIV dementia 3How can identical twins be genetically different? 2How can identical twins be genetically different? 3
... Novagens PhageMaker System is optimized for maximum ... ligated with any bacteriophage l vector. Using a ... > 10^7 pfu/g arms (> 4 x 10^8 ... This one-tube system is extremely easy to use; ...
Gridded Cell Culture Petri Dish (20 mm molded in base), tissue-culture treated...
Chicken Anti-Human DNA-directed RNA Polymerase II 7.6 Kd Polypeptide (POLR2L Polyclonal AntibodyOther Sub-Family: not assigned-Other Applications: ELISA, Western Blot...
... cultured in RPMI 1640 with 2 mM L-glutamine ... In order to keep the antigens in ... The cells are arrayed on a 12-well ... surface specifically treated to enhance cellular attachment and ...
Biology Products: